Aptevo Therapeutics Inc
aptevotherapeutics.comWhat Do They Do?
Develops bispecific and trispecific immunotherapy candidates for cancer treatment, including therapies aimed at blood cancers and solid tumors.
10-K for FY2025, filed Mar 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$6.4MView ↗
- ▲ +2% (Loss)
- vs −$6.2M in Q2 FY2025
-
May 27, 2026
Aptevo entered a radiopharmaceutical development collaboration with Niowave
The 50/50 collaboration covers up to three radiopharmaceutical oncology programs using Aptevo molecules and Niowave radioisotopes.
Sources
8-K, filed May 27, 2026
SEATTLE, WA and LANSING, MI – May 27, 2026 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company developing…View ↗
Who Do They Compete With?
Competes with Affimed, ImmunoGen, Innate Pharma, Sanofi, Macrogenics, Gilead, Menarini Group, Molecular Partners, Lava, Cullinan, Novartis, Bio-Path, Shattuck Labs, Syros Pharma, Faron Pharma, ALX Oncology, Crescendo Biologics, Boehringer Ingelheim, Amgen, and Hoffmann-La Roche
10-K for FY2025, filed Mar 26, 2026Mipletamig: We anticipate that mipletamig would compete with other agents targeting both CD123 and non-CD123 that are in development for…View ↗
Loading...
